Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax

Pfizer

The Biden administration is planning to stop paying for Covid vaccines and treatments, a move that could buoy some Covid stocks. The post Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions appeared first on Investor's Business Daily.

Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions

Advanced Micro Devices

Blackstone Group

Cigna

ServiceNow

NVIDIA

Tesla

Uber

Vertex Pharmaceuticals

Sales growth is a very important financial metric that investors consider before making a buy decision.

These Are The Biggest Companies with Over 30% Sales Growth

Investors traded down the company's shares following news of a top-level managerial change.

Why Moderna Stock Was Wilting on Wednesday

The company has stood pat while other businesses have been busy with M&A.

Has Moderna Made a Bear Market Blunder?

Moderna Inc on Wednesday named former PerkinElmer executive James Mock as the company's chief financial officer, effective Sept. 6.

Moderna names PerkinElmer exec as new CFO

Moderna Inc. MRNA, -4.99% said Wednesday that Chief Financial Officer David Meline will retire, effective Sept. 6. Moderna shares fell 0.6% in premarket trading.

Moderna CFO David Meline to retire, to be succeed by PerkinElmer's James Mock

PerkinElmer

CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel.

James Mock Joins Moderna as Chief Financial Officer

There wasn't any negative news from the vaccine maker.

Why Moderna Stock Is Sliding Today

SAN MATEO, Calif.--(BUSINESS WIRE)--Moderna recently conducted a digitally enabled, at-home study examining COVID-19 antibody response over time, made possible by Evidation. A preprint published on MedRxiv, Antibody Response Following COVID-19 Boosters During the Omicron Wave in the United States: A Decentralized, Digital Health, Real-World Study, reports individuals who received Moderna primary shots and boosters had more durable antibody levels than those who received Pfizer. This observation

Evidation Enables First of Its Kind Moderna Study to Track COVID Vaccine Response in Real Life

The biotech's COVID-19 vaccine sales could be about to receive a boost.

Why Moderna Stock Climbed Today

The pioneering COVID-19 fighter claims another victory, and shareholders are celebrating.

Is Moderna Stock a Buy Now After the U.K.'s Omicron Vaccine Approval?

Moderna, Inc (NASDAQ: MRNA) spiked up almost 5% off Friday's closing price at one point on Monday, before hitting a resistance level at the $179 level and running into a group of sellers.

Is Moderna Preparing To Soar 20% And Tackle This Big Level? What To Watch On The Weekly Chart

The U.K.'s regulatory authority just approved Moderna's (NASDAQ: MRNA ) bivalent Covid-19 booster vaccine called mRNA-1273.214. Bivalent means it addresses two strains of Covid-19, and this particular booster shot targets the omicron variant as well as the original virus.

MRNA Stock Alert: What to Know as U.K. Approves Updated Moderna Booster

The U.K. regulator has become the first to authorize Moderna's bivalent COVID vaccine booster for use in adults aged 18 and older.

U.K. regulator is first to authorize Moderna's bivalent COVID booster for adults aged 18 and older

The booster shot targets two coronavirus variants and contains half omicron-specific vaccine and half original vaccine.

Moderna's Omicron Booster Approved In The U.K. In World First

U.K. regulators approve an updated Moderna Covid-19 booster shot, the first bivalent Covid-19 booster shot to be approved anywhere in the world.

U.K. Approves Moderna's Updated Covid-19 Booster

Moderna Inc. MRNA, -0.37% said Monday the U.K. regulator has authorized its bivalent COVID vaccine booster for use in adults aged 18 and older. The Medicines and Healthcare products Regulatory Agency gave the nod to the booster dubbed mRNA-1273.214 which targets the original virus strain, as well as the omicron variant.

UK regulator authorizes Moderna bivalent COVID vaccine booster for adults aged 18 and older

Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 CAMBRIDGE, MA / ACCESSWIRE / August 15, 2022 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted conditional authorization for the use of the Omicron-containing bivalent COVID-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron▼) as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK

Forget taking two to three Covid shots a year. Moderna hopes to roll out a single-dose annual booster to cover the coronavirus, the flu and another common respiratory virus within the next five years.

Moderna CEO says Covid vaccines will evolve like 'an iPhone'

While Moderna's revenue grew by about 9% year-over-year to $4.

With Growth Slowing, Is Moderna Stock Still Worth A Look?

Pfizer is pursuing M&A with its profits from selling Covid-19 vaccines. Rival Moderna is doing stock buybacks and developing its own pipeline of drugs.

Pfizer and Moderna Take Different Paths as Vaccine Boom Ends

Contractually remaining doses of Moderna's COVID-19 vaccine (Spikevax, mRNA-1273) will be converted to Moderna's next generation Omicron-containing bivalent vaccines CAMBRIDGE, MA / ACCESSWIRE / August 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an amendment to its agreement with the European Commission (EC) to convert contractually agreed doses of Moderna's COVID-19 vaccine (Spikevax, mRNA-1273) to the Company's Omicron-containing bivalent vaccines for supply in 2022, pending regulatory approval. In addition, the EC has agreed to purchase an additional 15 million doses of Omicron-containing vaccine booster candidates from Moderna.

Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses

Bio-Techne

MRNA vs. TECH: Which Stock Is the Better Value Option?

MRNA vs. TECH: Which Stock Should Value Investors Buy Now?

Your portfolio is counting on you to pass the tests.

Prediction: This Bear Market Will Test Your Resolve In (At Least) 3 Ways

VanEck Vectors Biotech ETF

Amplify Treatments Testing & Advancements ETF

Invesco Nasdaq Biotechnology ETF

Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in its latest quarterly report, along with a share buyback plan. On Wednesday, the Invesco Nasdaq Biotechnology ETF (IBBQ) increased 4.2%, the ETFMG Treatments Testing and Advancements ETF (GERM) advanced 5.

News for Moderna Stock (MRNA)